Pharmaceutical composition

Abstract

Disclosed are novel pharmaceutical compositions containing N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2, 4, 7-trioxo-3, 4, 6, 7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethyl sulfoxide solvate, methods of using the compositions in therapy and processes for preparing the same.

What is claimed is:  
     
       1. A pharmaceutical tablet comprising:
 a) an amount of a drug, which is N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2, 4, 7-trioxo-3, 4, 6, 7-tetrahydro-2 H-pyrido[4,3- d]pyrimidin-1-yl]phenyl}acetamide dimethyl sulfoxide solvate; selected from: about 0.5635 mg, about 1.127 mg, and about 2.254 mg; wherein, 
 b) at least 50% of the drug particles have a particle size of 30 micron or less. 
 
     
     
       2. The pharmaceutical tablet, according to  claim 1 , comprising:
 a) an amount of a drug, which is N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo- phenylamino)-6,8-dimethyl-2, 4, 7-trioxo-3, 4, 6, 7-tetra hydro-2 H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethyl sulfoxide solvate; selected from: about 0.5635 mg, about 1.127 mg, and about 2.254 mg; wherein, 
 b) at least 50% of the drug particles have a particle size of 30 micron or less; and 
 c) the tablet contains from about 25% to about 89% by weight of one or more diluents, where the diluents are substantially free of water. 
 
     
     
       3. The pharmaceutical tablet, according to  claim 1 , comprising:
 a) an amount of a drug, which is N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo- phenylamino)-6,8-dimethyl-2, 4, 7-trioxo-3, 4, 6, 7-tetra hydro-2 H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethyl sulfoxide solvate; selected from: about 0.5635 mg, about 1.127 mg, and about 2.254 mg; wherein, 
 b) at least 50% of the drug particles have a particle size of 30 micron or less; 
 c) the tablet contains from about 25% to about 89% by weight of one or more diluents selected from: microcrystalline cellulose, powdered cellulose, pregelatinized starch, starch, lactose, Di-calcium phosphate, lactitol, mannitol, sorbitol and maltodextrin, where the diluents are substantially free of water. 
 
     
     
       4. The pharmaceutical tablet, according to  claim 1 , comprising:
 a) an amount of a drug, which is N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo- phenylamino)-6,8-dimethyl-2, 4, 7-trioxo-3, 4, 6, 7-tetrahydro-2 H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethyl sulfoxide solvate; selected from: about 0.5635 mg, about 1.127 mg, and about 2.254 mg; wherein, 
 b) at least 50% of the drug particles have a particle size of 30 micron or less; 
 c) the tablet contains from about 25% to about 89% by weight of one or more diluents selected from: microcrystalline cellulose, powdered cellulose, pregelatinized starch, starch, lactose, Di-calcium phosphate, lactitol, mannitol, sorbitol and maltodextrin, where the diluents are substantially free of water; and 
 d) the tablet is film coated. 
 
     
     
       5. The pharmaceutical tablet, according to  claim 1 , comprising:
 a) an amount of a drug, which is N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo- phenylamino)-6,8-dimethyl-2, 4, 7-trioxo-3, 4, 6, 7-tetrahydro-2 H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethyl sulfoxide solvate; selected from: about 0.5635 mg, about 1.127 mg, and about 2.254 mg; wherein, 
 b) at least 50% of the drug particles have a particle size of 30 micron or less; 
 c) the tablet is produced on a scale suitable to prepare at least about 50,000 tablets; 
 d) the tablet contains from about 25% to about 89% by weight of one or more diluents selected from: microcrystalline cellulose, powdered cellulose, pregelatinized starch, starch, lactose, Di-calcium phosphate, lactitol, mannitol, sorbitol and maltodextrin, where the diluents are substantially free of water; and 
 e) the tablet is film coated. 
 
     
     
       6. The pharmaceutical tablet, according to  claim 1 , comprising:
 a) an amount of a drug, which is N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo- phenylamino)-6,8-dimethyl-2, 4, 7-trioxo-3, 4, 6, 7-tetrahydro-2 H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethyl sulfoxide solvate; selected from: about 0.5635 mg, about 1.127 mg, and about 2.254 mg; wherein, 
 b) at least 50% of the drug particles have a particle size of 30 micron or less; 
 c) the tablet is produced on a scale suitable to prepare at least about 50,000 tablets; 
 d) the tablet contains from about 25% to about 89% by weight of one or more diluents selected from: microcrystalline cellulose, powdered cellulose, pregelatinized starch, starch, lactose, Di-calcium phosphate, lactitol, mannitol, sorbitol and maltodextrin, where the diluents are substantially free of water; and 
 e) the tablet is film coated and wherein the film coating contains a colorant. 
 
     
     
       7. The pharmaceutical tablet, according to  claim 1 , comprising:
 a) an amount of a drug, which is N-{3-[3-cyclopropyl-5- (2-fluoro-4-iodo- phenylamino)-6,8-dimethyl-2, 4, 7-trioxo-3, 4, 6, 7-tetrahydro-2 H-pyrido [4,3-d]pyrimidin-1-yl]phenyl }acetamide dimethyl sulfoxide solvate; selected from: about 0.5635 mg, about 1.127 mg, and about 2.254 mg; wherein, 
 b) at least 50% of the drug particles have a particle size of 30 micron or less; 
 c) the tablet is produced on a scale suitable to prepare at least about 50,000 tablets; 
 d) the tablet contains from about 25% to about 89% by weight of one or more diluents selected from: microcrystalline cellulose, powdered cellulose, pregelatinized starch, starch, lactose, Di-calcium phosphate, lactitol, mannitol, sorbitol and maltodextrin, where the diluents are substantially free of water; 
 e) the tablet is film coated and wherein the film coating contains a colorant that contains iron oxide; and 
 f) amount of unsolvated drug does not exceed about 20%. 
 
     
     
       8. A pharmaceutical tablet comprising:
 a) an amount of a drug, which is N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo- phenylamino)-6,8-dimethyl-2, 4, 7-trioxo-3, 4, 6, 7-tetrahydro-2 H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethyl sulfoxide solvate; selected from: about 0.5635 mg, about 1.127 mg, and about 2.254 mg; wherein, 
 b) the drug particles are micronized. 
 
     
     
       9. The pharmaceutical tablet, according to  claim 8 , comprising:
 a) an amount of a drug, which is N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo- phenylamino)-6,8-dimethyl-2, 4, 7-trioxo-3, 4, 6, 7-tetrahydro-2 H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethyl sulfoxide solvate; selected from: about 0.5635 mg, about 1.127 mg, and about 2.254 mg; wherein, 
 b) the drug particles are micronized; and 
 c) the tablet contains from about 25% to about 89% by weight of one or more diluents, where the diluents are substantially free of water. 
 
     
     
       10. The pharmaceutical tablet, according to  claim 8 , comprising:
 a) an amount of a drug, which is N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo- phenylamino)-6,8-dimethyl-2, 4, 7-trioxo-3, 4, 6, 7-tetrahydro-2 H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethyl sulfoxide solvate; selected from: about 0.5635 mg, about 1.127 mg, and about 2.254 mg; wherein, 
 b) the drug particles are micronized; 
 c) the tablet contains from about 25% to about 89% by weight of one or more diluents selected from: microcrystalline cellulose, powdered cellulose, pregelatinized starch, starch, lactose, Di-calcium phosphate, lactitol, mannitol, sorbitol and maltodextrin, where the diluents are substantially free of water. 
 
     
     
       11. The pharmaceutical tablet, according to  claim 8 , comprising:
 a) an amount of a drug, which is N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo- phenylamino)-6,8-dimethyl-2, 4, 7-trioxo-3, 4, 6, 7-tetrahydro-2 H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethyl sulfoxide solvate; selected from: about 0.5635 mg, about 1.127 mg, and about 2.254 mg; wherein, 
 b) the drug particles are micronized; 
 c) the tablet contains from about 25% to about 89% by weight of one or more diluents selected from: microcrystalline cellulose, powdered cellulose, pregelatinized starch, starch, lactose, Di-calcium phosphate, lactitol, mannitol, sorbitol and maltodextrin, where the diluents are substantially free of water; and 
 d) the tablet is film coated. 
 
     
     
       12. The pharmaceutical tablet, according to  claim 8 , comprising: a) an amount of a drug, which is N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo- phenylamino)-6,8-dimethyl-2, 4, 7-trioxo-3, 4, 6, 7-tetrahydro-2 H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethyl sulfoxide solvate; selected from: about 0.5635 mg, about 1.127 mg, and about 2.254 mg; wherein,
 b) the drug particles are micronized; 
 c) the tablet is produced on a scale suitable to prepare at least about 50,000 tablets; 
 d) the tablet contains from about 25% to about 89% by weight of one or more diluents selected from: microcrystalline cellulose, powdered cellulose, pregelatinized starch, starch, lactose, Di-calcium phosphate, lactitol, mannitol, sorbitol and maltodextrin, where the diluents are substantially free of water; and 
 e) the tablet is film coated. 
 
     
     
       13. The pharmaceutical tablet, according to  claim 8 , comprising:
 a) an amount of a drug, which is N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo- phenylamino)-6,8-dimethyl-2, 4, 7-trioxo-3, 4, 6, 7-tetrahydro-2 H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethyl sulfoxide solvate; selected from: about 0.5635 mg, about 1.127 mg, and about 2.254 mg; wherein, 
 b) the drug particles are micronized; 
 c) the tablet is produced on a scale suitable to prepare at least about 50,000 tablets; 
 d) the tablet contains from about 25% to about 89% by weight of one or more diluents selected from: microcrystalline cellulose, powdered cellulose, pregelatinized starch, starch, lactose, Di-calcium phosphate, lactitol, mannitol, sorbitol and maltodextrin, where the diluents are substantially free of water; and 
 e) the tablet is film coated and wherein the film coating contains a colorant. 
 
     
     
       14. The pharmaceutical tablet, according to  claim 8 , comprising:
 a) an amount of a drug, which is N-{3-[3-cyclopropyl-5- (2-fluoro-4-iodo- phenylamino)-6,8-dimethyl-2, 4, 7-trioxo-3, 4, 6, 7-tetrahydro-2 H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethyl sulfoxide solvate; selected from: about 0.5635 mg, about 1.127 mg, and about 2.254 mg; wherein, 
 b) the drug particles are micronized; 
 c) the tablet is produced on a scale suitable to prepare at least about 50,000 tablets; 
 d) the tablet contains from about 25% to about 89% by weight of one or more diluents selected from: microcrystalline cellulose, powdered cellulose, pregelatinized starch, starch, lactose, Di-calcium phosphate, lactitol, mannitol, sorbitol and maltodextrin, where the diluents are substantially free of water; 
 e) the tablet is film coated and wherein the film coating contains a colorant that contains iron oxide; and 
 f) amount of unsolvated drug does not exceed about 20%. 
 
     
     
       15. The pharmaceutical tablet according to  claim 9  wherein: the tablet contains from about 25% to about 89% by weight of one or more diluents selected from: microcrystalline cellulose and mannitol. 
     
     
       16. A process for preparing pharmaceutical tablets containing an amount of a drug, which is N-{3[3-cyclopropyl-5-(2-fluoro-4-iodo- phenylamino)-6,8-dimethyl-2, 4, 7-trioxo-3, 4, 6, 7-tetrahydro-2 H-pyrido[4,3-d]pyrimidin-1-yl]phenyl }acetamide dimethyl sulfoxide solvate; selected from: about 0.5635 mg, about 1.127 mg, and about 2.254 mg, which process comprises the steps of;
 admixing: N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo- phenylamino)-6,8-dimethyl-2, 4, 7-trioxo-3, 4, 6, 7-tetrahydro-2 H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethyl sulfoxide solvate, one or more excipients, where the excipients are substantially free of water, and further excipients, to form a mixture; and compressing the mixture into tablets; provided: each tablet contains N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo- phenylamino)-6,8-dimethyl-2, 4, 7-trioxo-3, 4, 6, 7-tetrahydro-2 H-pyrido[4,3d]pyrimidin-1-yl]phenyl}acetamide dimethyl sulfoxide solvate, in an amount selected from: about 0.5635 mg, about 1.127 mg, and about 2.254 mg; and at least 50% of the drug particles have a particle size of 30 micron or less.